Lassa fever is a longstanding public health concern in West Africa. Recent molecular studies have confirmed the fundamental role of the rodent host (Mastomys natalensis) in driving human infections, but control and prevention efforts remain hampered by a limited baseline understanding of the disease's true incidence, geographical distribution and underlying drivers. Here, we show that Lassa fever occurrence and incidence is influenced by climate, poverty, agriculture and urbanisation factors. However, heterogeneous reporting processes and diagnostic laboratory access also appear to be important drivers of the patchy distribution of observed disease incidence. Using spatiotemporal predictive models we show that including climatic variability added retrospective predictive value over a baseline model (11% decrease in out-of-sample predictive error). However, predictions for 2020 show that a climate-driven model performs similarly overall to the baseline model. Overall, with ongoing improvements in surveillance there may be potential for forecasting Lassa fever incidence to inform health planning.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486829 | PMC |
http://dx.doi.org/10.1038/s41467-021-25910-y | DOI Listing |
J Prev Med Hyg
September 2024
College of Medicine Imo State University, Owerri, Imo State, Nigeria.
Introduction: Lassa fever (LF), a public health problem of great importance endemic in West Africa, is an acute and sometimes fatal viral haemorrhagic disease which leads to mortality. The current study assessed the knowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.
Methods: Descriptive study design and Cross sectional study design was used for this study.
Virol J
December 2024
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.
View Article and Find Full Text PDFBMC Public Health
December 2024
Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Background: Nigeria is an epicenter for Lassa fever. Ebonyi state is located in the South-Eastern region of Nigeria where a high burden of Lassa fever has been reported. Therefore, this study was designed to assess the epidemiology of Lassa fever, its seasonality, trend, and mortality predictors in Ebonyi state, South-East, Nigeria.
View Article and Find Full Text PDFAm J Trop Med Hyg
December 2024
Department of Medicine, Section of Infectious Diseases, School of Medicine, Tulane University, New Orleans, Louisiana.
The viral hemorrhagic fevers Lassa fever (LF) and Ebola virus disease (EVD) have been documented to cause long-term health problems in survivors. Limited studies have noted the presence of adverse reproductive health outcomes, including menstrual irregularities and pregnancy loss, after recovery from infection. The objective of this systematic review and meta-analysis is to summarize existing knowledge surrounding reproductive health in female survivors of LF and EVD.
View Article and Find Full Text PDFJ Gen Virol
December 2024
Laboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Lassa virus (LASV) is an Old World (OW) mammarenavirus that causes Lassa fever, a life-threatening acute febrile disease endemic in West Africa. Lymphocytic choriomeningitis virus (LCMV) is a worldwide-distributed, prototypic OW mammarenavirus of clinical significance that has been largely neglected as a human pathogen. No licensed OW mammarenavirus vaccines are available, and the current therapeutic option is limited to the off-label use of ribavirin, which offers only partial efficacy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!